Comparison of the efficacy of replication-defective adenovirus and Nyvac poxvirus as vaccine vectors in mice

Vaccine

Volumn 14, Issue 11, 1996, Pages 1083-1087

  Gonin, Patrick ^a   Oualikene, Wahiba ^a   Fournier, Annie ^a   Eloit, Marc ^a  

^a Ecl Natl V   (France)

Author keywords

Adenovirus; Poxvirus; Pseudorabies; Vaccine

Indexed keywords

VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSA; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; VACCINATION; VIRUS RECOMBINANT;

EID: 0030219942     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00226-Q     Document Type: Article

References (29)

1. 1 Prevec, L., Schneider, M., Rosenthal, K.L., Belbeck, L.W., Derbyshire, J.B. and Graham, F.L. Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Virol. 1989, 70, 429-434, erratum 2539
2. 2 Prevec, L., Campbell, J.B., Christie, B.S., Belbeck, L. and Graham, F.L. A recombinant human adenovirus vaccine against rabies. J. Infect. Dis. 1990, 161, 27-30
3. 3 Vernon, S.K., Murthy, S., Wilhelm, J., Chanda, P.K., Kalyan, N., Lee, S.G. and Hung, P.P. Ultrastructural characterization of human immunodeficiency virus type 1 gag-containing particles assembled in a recombinant adenovirus vector system. J. Gen. Virol. 1991, 72, 1243-1251
4. 4 Charlton, K.M., Artois, M., Prevec, L. et al. Oral vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch. Virol. 1992, 123, 169-179
5. 5 Caravokyri, C., Pringle, C.R. and Leppard, K.N. Human adenovirus type-5 recombinant expressing simian immunodeficiency virus macaque strain gag antigens. J. Gen. Virol. 1993, 74, 2819-2824
6. 6 Jacobs, S.C. A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge. Clin. Sci. 1993, 85, 117-122
7. 7 Natuk, R.J., Lubeck, M.D., Chanda, P.K. et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Human Retrovir. 1993, 9, 395-404
8. 8 Wesseling, J.G., Godeke, G.J., Schijns, V.E. et al. Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. J. Gen. Virol. 1993, 74, 2061-2069
9. 9 Zheng, B.J., Graham, F.L., Johnson, D.C., Hanke, T., McDermott, M.R. and Prevec, L. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 1993, 11, 1191-1198
10. 10 Chengalvala, M.V., Bhat, B.M., Bhat, R. et al. Immunogenicity of high expression adenovirus hepatitis B virus recombinant vaccines in dogs. J. Gen. Virol. 1994, 75, 125-131
11. 11 Ballay, A., Levrero, M., Buendia, M.A., Tiollais, P. and Perricaudet, M. In vitro and in vivo synthesis of the hepatitis B surface antigen and of the receptor for polymerised human serum albumin from recombinant human adenoviruses. EMBO J. 1985, 4, 3861-3865
12. 12 Eloit, M., Gilardi-Hebenstreit, P., Toma, B. and Perricaudet, M. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gD and its use as a live vaccine. J. Gen. Virol. 1990, 71, 2425-2431
13. 13 Levrero, M., Barban, V., Manteca, S. et al. Defective and non-defective adenovirus vectors for expressing foreign genes in vitro and in vivo. Gene 1991, 101, 195-202
14. 14 Ragot, T., Finerty, S., Watkins, P.E., Perricaudet, M. and Morgan, A.J. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J. Gen. Virol. 1993, 74, 501-507
15. 15 Oualikene, W., Gonin, P. and Eloit, M. Short and long term dissemination of deletion mutants of adenovirus in permissive (cotton-rat) and non-permissive (mouse) species. J. Gen. Virol. 1994, 75, 2765-2768
16. 16 Oualikene, W., Gonin, P. and Eloit, M. Lack of evidence of phenotypic complementation of E1A/E1B-deleted adenovirus type 5 upon superinfection by wild-type virus in the cotton-rat. J. Virol. 1995, 69, 10, in press
17. 17 Tartaglia, J., Perkus, M.E., Taylor, J. et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992, 188, 217-232
18. 18 Marchioli, C., Yancey, R., Petrovskis, E., Timmins, J. and Post, L. Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells. J. Gen. Virol. 1987, 61, 3977-3982
19. 19 Eloit, M., Fargeaud, D., Vannier, P. and Toma, B. Development of an ELISA to differentiate between animals either vaccinated with or infected by Aujeszky's disease virus. Vet. Rec. 1989, 124, 91-94
20. 20 Adam, M., Lepottier, M.F. and Eloit, E. Vaccination of pigs with replication-defective adenovirus vectored vaccines: the example of pseudorabies. Vet. Microbiol. 1994, 42, 205-215
21. 21 Brockmeier, S.L., Lager, K.M., Tartaglia, J., Rivière, M., Paoletti, E. and Mengeling, W.L. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet. Microbiol. 1993, 38, 41-58
22. 22 Rivière, M., Tartaglia, J., Perkus, M.E. et al. Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants. J. Virol. 1992, 66, 3424-3434
23. 23 Mengeling, W.L., Brockmeier, S.L. and Lager, K.M. Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII and gIII as a PR vaccine for pigs. Arch. Virol. 1994, 134, 256-269
24. 24 Goebel, S.J., Johnson, G.P., Perkus, M.E., Davis, S.W., Winslow, J.P. and Paoletti, E. The complete DNA sequence of vaccinia virus. Virology 1990, 179, 247-266
25. 25 Goebel, S.J., Johnson, G.P., Perkus, M.E., Davis, S.W., Winslow, J.P. and Paoletti, E. Appendix to: "The complete DNA sequence of vaccinia virus". Virology 1990, 179, 517-563
26. 26 Vos, J.C. and Stunnenberg, H.G. Depression of a novel class of vaccinia virus genes upon DNA replication. EMBO J. 1988, 7, 3487-3492
27. 27 Ganne, V., Eloit, M., Laval, A., Adam, M. and Trouve, G. Enhancement of the efficacy of replication-defective adenovirus vectored vaccine by the addition of oil adjuvants. Vaccine 1993, 12, 1190-1196
28. 28 Taylor, J., Weiberg, R., Tartaglia, J. et al. Non replicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992, 187, 321-328
29. 29 Ulmer, J.B., Donelly, J.H., Parker, S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749